Zazueta LRM, Hierro OS, Achell NL, Jaimes HV

Language: Spanish
References: 18
Page: 207-214
PDF size: 182.46 Kb.

ABSTRACT

Langerhans cell histiocytosis was first described in the 19th century, and since then has been described with different names given its poorly known etiology. The exact causes of this entity are still unknown, but with the use of new technologies and new recent observations it has been possible to classify it based on different microscopic findings. Some authors believe that Langerhans cell histiocytosis is a disease that manifests itself with a wide range of clinical presentations previously described as different diseases. Other authors believe that these different clinical presentations are in fact different stages of the disease. Clinical manifestations can thus be variable, and range from a localized skin problem to a systemic disease that can threaten the patient’s life. We report a case diagnosed and successfully treated in our hospital.

REFERENCES

1. Coppes ZA, Egeler RM. “The Langerhans cell histiocytosis X files revealed”. British Journal of Hematology 2002; 116: 3-9.

2. Egeler RM, Zantinga AR, Coppes MX. “Paul Langerhans Jr. (1847-1888): A short life, yet two eponymic legacies”. Medical and Pediatric Oncology 1994; 22: 129-132.

3. Satter EK, Gendernalik SB, Galekas KJ. “Diffuse xanthogrnulomatous dermatitis and systemic Langerhans cell histocytosis: A novel case that demonstrates bridgning between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis”. J Am Acad Dermatol 2009; 60: 841- 848.

4. Milena AT, Restrepo R, Ochoa A. “Histiocitosis de células de Langerhans”. Rev Asoc Col Dermatol 2009; 17(1): 34-44.

5. Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, et al. “Contemporary classification of histiocytic disorders”. Medical and Pediatric Oncology 1997; 29: 157-166.

6. Ferrando J. “Histiocitosis”. Protocolos diagnósticos y terapéuticos en dermatología pediátrica 2000: 159-165.

7. Zachary CB, MacDonald DM. “Hand-Schuller-Christian disease with secondary cutaneous involvement”. Clin Exp Dermatol 1983; 8: 177-183.

8. Neumann B, Hu W, Nigro K, Gilliam AC. “Agressive histiocytic disorders that can involve the skin”. J Am Acad Dermatol 2007; 56: 302-316.

9. Slater JM, Swarm JO. “Eosinophilic granuloma of the bone”. Medical and Pediatric Oncology 1980; 8: 151-164.

10. Divaris DX, Ling FC, Prentice RS. “Congenital self-healing histiocytosis”. Am J Dermatopathol 1991; 13: 481-487

11. Satter EK, High WA. “Langerhans cell histiocytosis: A review of the current recomendatios of the Histiocyte Society”. Pediatric Dermatology 2008; 3: 292-295.

12. Risdall RJ, Dehner LP, Duray P, Kobrinsky N, Robinson L. “Histiocytosis X (Langerhans’ cell histiocytosis) Pronostic role of histopathology”. Arch Pathol Lab Med 1983; 107: 59-63.

13. Vogel CA, Aughenbaugh W, Sharata H. “Excimer laser as adjuvant therapy for adult cutaneous Langerhans cell histiocytosis”. Arch Dermatol 2008; 144(10): 1-4.

14. Arico M, Colella R, Conter V, Indolfi P, Pession A, Santoro N, et al. “Cyclosporine therapy for refractory Langerhans cell histiocytosis”. Medical and Pediatric Oncology 1995; 25: 12-16.

15. Stebut EV, Schandmand-Fischer S, Bräuninger W. “Successful treatment of adult multisystemic Langerhans cell histiocytosis with Psoralen-UVA, Prednisolona, Mercaptopurine and Vinblastine”. Arch Dermatol 2008; 144(5): 649-653.

16. Arceci RJ, Brenner MK, Pritchard J. “Controversies and new approaches to treatment of Langerhans cell histiocytosis”. Hematol Clin North Am 1998; 12: 339-357.

17. Battistella M, Fraitag S, Hamel DT, Brousse N, Prost YD, Bodemer C. “Neonatal and early infantile cutaneous Langerhans cell histiocytosis”. Arch Dermatol 2010; 146(2): 149-156.

18. Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H. “Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator”. Med Pediatr Oncol 2002; 39: 581-585.